WO1997038085A3 - Genes amplified in cancer cells - Google Patents

Genes amplified in cancer cells Download PDF

Info

Publication number
WO1997038085A3
WO1997038085A3 PCT/US1997/005930 US9705930W WO9738085A3 WO 1997038085 A3 WO1997038085 A3 WO 1997038085A3 US 9705930 W US9705930 W US 9705930W WO 9738085 A3 WO9738085 A3 WO 9738085A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
cancer
gene
cells
genes
Prior art date
Application number
PCT/US1997/005930
Other languages
French (fr)
Other versions
WO1997038085A2 (en
Inventor
Helene Smith
Ling-Chun Chen
Original Assignee
California Pacific Med Center
Helene Smith
Chen Ling Chun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1996/009286 external-priority patent/WO1996039516A2/en
Priority claimed from US08/678,280 external-priority patent/US5776683A/en
Application filed by California Pacific Med Center, Helene Smith, Chen Ling Chun filed Critical California Pacific Med Center
Priority to EP97920293A priority Critical patent/EP0944651A2/en
Priority to AU24521/97A priority patent/AU2452197A/en
Priority to JP9536486A priority patent/JP2000509256A/en
Publication of WO1997038085A2 publication Critical patent/WO1997038085A2/en
Publication of WO1997038085A3 publication Critical patent/WO1997038085A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

New methods are disclosed for detecting cancer associated genes, and obtaining corresponding cDNA sequences. The methods involve supplying RNA preparations from control cells, and from a plurality of different cancer cells that share a duplicated or deleted gene in the same region of a chromosome. Amplified cDNA copies are displayed, and then selected based on differences in abundance of RNA between preparations. Optional additional screening steps involve surveying panels of cancer cells using the cDNA for RNA overabundance with or without gene duplication. The identified genes can be used in turn to develop materials and techniques for diagnosing and treating the underlying cancer. Four novel genes associated with cancer have been identified. In at least about 60 % of the breast cancer cell lines tested, RNA hybridizing with the cDNAs were substantially more abundant than in normal cells. Most of the cell lines also showed a duplication of the corresponding gene, which probably contributed to the increased level of RNA in the cell. However, for each of the four genes, there were some cell lines which had RNA overabundance without gene duplication. This suggests that the gene product is sufficiently important to the cancer process that cells will use several alternative mechanisms to achieve increased expression.
PCT/US1997/005930 1996-04-10 1997-04-09 Genes amplified in cancer cells WO1997038085A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97920293A EP0944651A2 (en) 1996-04-10 1997-04-09 Genes amplified in cancer cells
AU24521/97A AU2452197A (en) 1996-04-10 1997-04-09 Genes amplified in cancer cells
JP9536486A JP2000509256A (en) 1996-04-10 1997-04-09 Genes amplified in cancer cells

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1516796P 1996-04-10 1996-04-10
US60/015,167 1996-04-10
PCT/US1996/009286 WO1996039516A2 (en) 1995-06-05 1996-06-05 Targets for breast cancer diagnosis and treatment
USPCT/US96/09286 1996-06-05
US1920296P 1996-06-06 1996-06-06
US60/019,202 1996-06-06
US08/678,280 1996-07-11
US08/678,280 US5776683A (en) 1996-07-11 1996-07-11 Methods for identifying genes amplified in cancer cells

Publications (2)

Publication Number Publication Date
WO1997038085A2 WO1997038085A2 (en) 1997-10-16
WO1997038085A3 true WO1997038085A3 (en) 1998-02-19

Family

ID=27486464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005930 WO1997038085A2 (en) 1996-04-10 1997-04-09 Genes amplified in cancer cells

Country Status (4)

Country Link
EP (1) EP0944651A2 (en)
JP (1) JP2000509256A (en)
AU (1) AU2452197A (en)
WO (1) WO1997038085A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170864A1 (en) 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US20030105298A1 (en) 1998-06-16 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7351543B2 (en) 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7319008B2 (en) 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
US7244817B2 (en) 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US7244428B2 (en) 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7399828B2 (en) 1998-09-24 2008-07-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7402661B2 (en) 1998-10-06 2008-07-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7300758B2 (en) 1999-12-09 2007-11-27 Genetech, Inc. Nucleic acid underexpressed in esophageal tumor
US7423127B2 (en) 1999-12-09 2008-09-09 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
US7288384B2 (en) 1999-12-09 2007-10-30 Genentech, Inc. Antibodies to polypeptides encoded by a nucleic acid underexpressed in esophageal tumor
US7442765B2 (en) 2000-08-24 2008-10-28 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
US7989167B2 (en) * 2006-11-13 2011-08-02 Val-Chum L.P. Method of prognosing and diagnosing hereditary spastic paraplegia, mutant nucleic acid molecules and polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
WO1992021771A1 (en) * 1991-06-03 1992-12-10 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1991002062A2 (en) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. C-erbb-2 external domain: gp75
WO1992021771A1 (en) * 1991-06-03 1992-12-10 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADNANE J ET AL: "BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.", ONCOGENE, APR 1991, 6 (4) P659-63, ENGLAND, XP000607852 *
BERNS EM ET AL: "SPORADIC AMPLIFICATION OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR GENE IN HUMAN BREAST TUMORS", CANCER RES;52(4):1036-9 1992, XP002037748 *
BIECHE I ET AL: "LOSS AND GAIN OF DISTINCT REGIONS OF CHROMOSOME 1Q IN PRIMARY BREAST-CANCER", CLINICAL CANCER RESEARCH, 1995, 1, 123-127, XP000609027 *
CHEN Z ET AL: "Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas.", MOL MED, JAN 1995, 1 (2) P153-60, UNITED STATES, XP000607858 *
EMBL database ion number D83780 16-03- Nomura n. Human mRNA for KIA *
EMBL database ion number H15342 Hillie t al. The Washu-Me T project 03-07-95 *
LIANG P ET AL: "DIFFERENTIAL DISPLAY OF EUKARYOTIC MESSENGER RNA BY MEANS OF THE POLYMERASE CHAIN REACTION", SCIENCE, vol. 257, no. 5072, 14 August 1992 (1992-08-14), pages 967 - 971, XP000508268 *
NAGASE T ET AL: "Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1.", DNA RES, FEB 29 1996, 3 (1) P17-24, JAPAN, XP002037754 *
SLAMON DJ ET AL: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.", SCIENCE, MAY 12 1989, 244 (4905) P707-12, UNITED STATES, XP002019974 *
WATSON MA ET AL: "Isolation of differentially expressed sequence tags from human breast cancer.", CANCER RES, SEP 1 1994, 54 (17) P4598-602, UNITED STATES, XP002019977 *

Also Published As

Publication number Publication date
AU2452197A (en) 1997-10-29
JP2000509256A (en) 2000-07-25
WO1997038085A2 (en) 1997-10-16
EP0944651A2 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
WO1997038085A3 (en) Genes amplified in cancer cells
WO1996039516A3 (en) Targets for breast cancer diagnosis and treatment
De Crombrugghe et al. Regulation of lac mRNA synthesis in a soluble cell-free system
Hanawalt et al. Stranded in an active gene
Arndt et al. A suppressor of a HIS4 transcriptional defect encodes a protein with homology to the catalytic subunit of protein phosphatases
Wells et al. Telomere-related sequences at interstitial sites in the human genome
Toyoda et al. Regulation of glutathione peroxidase mRNA level by dietary selenium manipulation
Travers et al. Oestrogen-induced expression of oncogenes in the immature rat uterus
EP0792931A3 (en) Products and methods for controlling the suppression of the neoplastic phenotype
Goshorn et al. Genetic analysis of prototrophic natural variants of Candida albicans.
EE04453B1 (en) Lymphotoxin-α / β complexes and anti-lymphotoxin-receptor antibodies as antitumor agents
Roth et al. Transfer RNA and the control of the histidine operon
DE69433978T2 (en) METHOD OF THE SPECIFIC DERIVATION OF GENES BY DNA METHYLATION
PT1003865E (en) Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection
Tatematsu et al. Precocious differentiation of immature chief cells in fundic mucosa of infant rats induced by hydrocortisone
EP0045573A3 (en) Eukaryotic autonomously replicating segment
Schäfer et al. Mitochondrial genes in Neurospora: A single cistron for ribosomal RNA
Maroni et al. Genetic control of Adh expression in Drosophila melanogaster
Brazill et al. Changing levels of UV light and carcinogen-induced unscheduled DNA synthesis in mouse oocytes during meiotic maturation
Vielmetter et al. Genetic evidence for transfer of a single DNA strand during bacterial conjugation
AU2311697A (en) Immuno-magnetic cell separation used in identification of genes associated with site-preferenced cancer methastasis formation
WO2000009655A3 (en) Genes amplified in cancer cells
Farrar et al. Interactions of photoactive DNAs with terminal deoxynucleotidyl transferase: identification of peptides in the DNA binding domain
Noyes et al. Genetic and cytological investigations in sexual Erigeron compositus (Asteraceae)
Sellem et al. Activation of a silent gene is accompanied by its demethylation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.44/97, UNDER INID(81)"DESIGNATED STATES",ADD"BA,CU,GH,LC,YU"

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.44/97, UNDER INID(30)"PRIORITY DATA",REPLACE"960409"BY"960410"AND"960710"BY"960711"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 332691

Country of ref document: NZ

Ref document number: 1997920293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997920293

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997920293

Country of ref document: EP